Skip to main content
SpringerLink
Log in

Akute myeloische Leukämie (AML, ANLL)

  • Chapter
Kompendium Internistische Onkologie

  • 13 Accesses

Zusammenfassung

Inzidenz: 2,5–3/100000/Jahr

Ätiologie: Gesicherte Auslöser sind ionisierende Strahlen, Benzol sowie antineoplastische Chemotherapeutika der Gruppen der alkylierenden Substanzen, Podophyllotoxine und Anthrazykline.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Adriaansen HJ et al. (1993) Detection of residual disease in AML patients by use of double immunological marker analysis for terminal deoxynucleotidyl transferase and myeloid markers. Leukemia 7: 472–481

    PubMed  CAS  Google Scholar 

  2. Adriaansen HJ et al. (1993) Acute myeloid leukemia M4 with bone marrow eosinophilia (M4Eo) and inv(16)(p 13g22) exhibits a specific immunophenotype with CD2 expression. Blood 81: 3043–3051

    PubMed  CAS  Google Scholar 

  3. Bain BJ (1990) Leukaemia diagnosis. Lippincott, Philadelphia

    Google Scholar 

  4. Bennett JM et al. (1985) Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 103: 626–629

    Article  Google Scholar 

  5. Bennett JM et al. (1985) Criteria for the diagnosis of acute leukemia of megakaryocyte lineage(M7). Ann Intern Med 103: 460–462

    Article  PubMed  CAS  Google Scholar 

  6. Bennett JM et al. (1991) Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-M0). Br J Haematol 78: 325–329

    Article  PubMed  CAS  Google Scholar 

  7. Borrow J et al. (1992) Molecular analysis of the t(15;17) translocation in acute promyelocytic leukaemia. In: Young BD (Hrsg) Bailliere’s Clinical Haematology. Bailliere Tindall, London Philadelphia Sydney Tokyo Toronto, pp 833–856

    Google Scholar 

  8. Brito-Babapulle F et al. (1987) Clinical and laboratory features of de novo acute myeloid leukaemia with trilineage myelodysplasia. Br J Haematol 66: 445–450

    Article  PubMed  CAS  Google Scholar 

  9. Büchner T (1993) Acute leukemia. Current Opinion in Hematology 173–182

    Google Scholar 

  10. Büchner T, Hiddemann W, Löffler G et al. (1991) Improved cure rate by very early intensification combined with prolonged maintenance chemotherapy in patients with acute myeloid leukemia: Data from the AML Cooperative Group. Semin Hematol 28 [Suppl 4]:76–79

    Google Scholar 

  11. Büchner T, Hiddemann W, Koenigsmann M et al. (1991) Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 78: 1190–1197

    PubMed  Google Scholar 

  12. Büchner T, Urbanitz D, Hiddemann W et al. (1985) Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia ( AML ): Two multicenter studies of the German AML Cooperative Group 3: 1583–1589

    Google Scholar 

  13. Cassileth PA, Lynch E, Hines JD et al. (1992) Varying intensity of postremission therapy in acute myeloid leukemia. Blood 79: 1924–1930

    PubMed  CAS  Google Scholar 

  14. Catovsky D et al. (1991) A classification of acute leukaemia for the 1990s. Ann Hematol 62: 16–21

    Article  PubMed  CAS  Google Scholar 

  15. Claxton DF et al. (1992) Correlation of CD2 expression with PML gene breakpoints in patients with acute promyelocytic leukemia. Blood 1992: 582–586

    Google Scholar 

  16. Cline MT (1994) The molecular basis of leukemia. NEJM 330: 328–336

    Article  PubMed  CAS  Google Scholar 

  17. Cuneo A et al. (1992) Correlation of cytogenetic patterns and clinicobiological features in adult acute myeloid leukemia expressing Iymphoid markers. Blood 79: 720–727

    PubMed  CAS  Google Scholar 

  18. Dillmann RO, Davis RB, Green MR et al. (1991) A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. Blood 78: 2520–2526

    Google Scholar 

  19. Ehninger G, Schuler U, Haas R (1993) Stellenwert der Knochenmarktransplantation in der Behandlung von Leukämien. Internist 34: 550–557

    PubMed  CAS  Google Scholar 

  20. Fenaux P, Le Deley MC, Castaigne Set al. (1993) Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. Blood 82: 3241–3249

    Google Scholar 

  21. Gorin NC, Labopin M, Meloni G et al. (1991) Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe: Further evidence of the role of marrow purging by mafosfamide. Leukemia 5: 896–904

    Google Scholar 

  22. Hansen OP, Pedersen-Biergaard J, Ellegaard J et al. (1991) Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. Leukemia 5: 510–516

    PubMed  CAS  Google Scholar 

  23. Hayat M, Jehn U, Willemze R et al. (1986) A randomized comparison of maintenance treatment with androgens, immunotherapy, and chemotherapy in adult acute myelogenous leukemia. Cancer 58: 617–623

    Article  PubMed  CAS  Google Scholar 

  24. Herzig RH, Lazarus HM, Wolff SN, Philips GL, Herzig GP (1992) High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia. J Clin Oncol 3: 992

    Google Scholar 

  25. Hiddemann W, Aul C, Maschmeyer G et al. (1992) High-dose versus intermediate-dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: Results of an age-adjusted randomized comparison. Haematology and Blood Transfusion 34: 412–417

    Google Scholar 

  26. Hiddemann W, Kreutzmann H, Strad K et al. (1987) High-dose cytosine arabinoside and mitoxantrone: A highly effective regimen in refractory acute myeloid leukemia. Blood 69: 774–779

    Google Scholar 

  27. Huang ME, Ye YC, Chen SR (1988) Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72: 567–572

    PubMed  CAS  Google Scholar 

  28. Jensen AW et al. (1991) Solitary expression of CD7 among T-cell antigens in acute myeloid leukemia: identification of a group of patients with similar T-cell receptor 13 and a rearrangements and course of disease suggestive of poor prognosis. Blood 78: 1292–1300

    PubMed  CAS  Google Scholar 

  29. Kita K et al. (1992) Phenotypical characteristics of acute myelocytic leukemia assosiated with the t(8;21)(q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD 19 together with stem cell antigen CD34. Blood 80: 470–477

    PubMed  CAS  Google Scholar 

  30. Kusnierz-Glaz CR, Normann D, Weinberg R et al. (1993) Subcutaneous low dose arabinosyl-cytosine and oral idarubicin in high risk adult acute myelogenous leukemia. Hematological Oncology, vol II: 1–8

    Google Scholar 

  31. Mandelli F, Vegna ML, Avvisati G et al. (1992) A randomized study of the efficacy of postconsolidation therapy in adult acute nonlymphocytic leukemia: a report of the Italian Cooperative Group GIMEMA 64: 166–172

    CAS  Google Scholar 

  32. Maschmeyer G, Link H, Hiddemann W et al. (1994) Eimpirische antimikrobielle Therapie bei neutropenischen Patienten. Med Klinik 89: 114–123

    CAS  Google Scholar 

  33. Neame PB et al. (1986) Classifying acute leukemia by immunophenotyping: a combined FAB-immunologic classification of AML. Blood 68: 1355–1362

    PubMed  CAS  Google Scholar 

  34. Nucifora G et al. (1993) Detection of DNA rearrangements in the AML1 and ETO loci and of an AML1/ETO fusion mRNA in patients with t(8;21) acute myeloid leukemia. Blood 81: 883–888

    PubMed  CAS  Google Scholar 

  35. Nucifora et al. (1993) Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood 82: 712–715

    PubMed  CAS  Google Scholar 

  36. Ohno R, Tomonaga M, Kobyashi T et al. (1990) Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. New Engl J Med 323: 871–877

    Article  PubMed  CAS  Google Scholar 

  37. Olopade OI et al. (1992) Clinical, morphologic, and cytogenetic characteristiss of 26 patients with acute erythroblastic leukemia. Blood 80: 2873–2882

    PubMed  CAS  Google Scholar 

  38. Preisler H, Davis RB, Kirshner J et al. (1987) Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study. Blood 69: 1441–1449

    PubMed  CAS  Google Scholar 

  39. Rai KR, Holland JF, Glidewell OJ et al. (1981) Treatment of acute myelocytic leukemia: a study by Cancer and Leukemia Group B. Blood 58: 1203–1212

    PubMed  CAS  Google Scholar 

  40. Rees JKH, Gray RG, Swirsky D, Hayhoe FG (1986) Principal results of the Medical Research Council’s 8th acute myeloid leukaemia trial. Lancet 29: 1236–1242

    Article  Google Scholar 

  41. Soekarman D et al. (1992) The translocation (6;9)(p23;q34) shows consistent rearrangement of two genes and defines a myeloproliferative disorder with specific clinical features. Blood 79: 2990–2997

    PubMed  CAS  Google Scholar 

  42. Vogler WR, Velez-Garcia E, Weiner RS, Flaum MA, Bartolucci AA, Omura GA, Gerber MC, Blanks PLC (1992) A phase III trial comparing idarubicin and daunorubicin combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study 10: 1103–1111

    CAS  Google Scholar 

  43. Vogler WR, Winton EF, Gordon DS, Raney MR, Go B, Meyer L (1984) A randomized comparison of postremission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group trial. Blood 63: 1039–1045

    PubMed  CAS  Google Scholar 

  44. Westbrook CA et al. (1992) Myeloid malignancies and chromosome 5 deletions. In: Young BD (Hrsg) Bailliere’s Clinical Haematology Bailliere Tindall, London Philadelphia Sydney Tokyo Toronto, pp 931–942

    Google Scholar 

  45. Wörmann B (1993) Implications of detection of minimal residual disease. Curr Opinion Oncol 5: 3–12

    Google Scholar 

  46. Young BD (1992) Cytogenetic and molecular analysis of chromosome 11g23 abnormalities in leukaemia. In: Young BD (ed) Bailliere’s Clinical Haematology. Bailliere Tindall, London Philadelphia Sydney Tokyo Toronto, pp 881–895

    Google Scholar 

  47. Zittoun R, Jehn U, Fiere D et al. (1989) Alternating u repeated postremission treatment in adult acute myelogenous leukemia: a randomized phase III study (AML6) of the EORTC Leukemia Cooperative Group. Blood 73: 896–906

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Th. Büchner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Lechner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. Schwarzinger
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik und Poliklinik, Innere Medizin IV, Abteilung Hämatologie/Onkologie, Martin-Luther-Universität Halle-Wittenberg, Ernst-Grube-Straße 40, D-06120, Halle/Saale, Deutschland

    Hans-Joachim Schmoll (Direktor) (Direktor)

  2. Klinik und Poliklinik für Innere Medizin II, Klinikum der Friedrich-Schiller-Universität Jena, Erlanger Allee 101, D-07740, Jena, Deutschland

    Klaus Höffken (Direktor) (Direktor)

  3. Medizinischen Klinik II, Schwerpunkt Onkologie und Hämatologie, Humboldt-Universität, Universitätsklinikum Charité, Schumannstraße 20/21, D-10117, Berlin, Deutschland

    Kurt Possinger (Direktor) (Direktor)

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Büchner, T., Lechner, K., Schwarzinger, I. (1997). Akute myeloische Leukämie (AML, ANLL). In: Schmoll, HJ., Höffken, K., Possinger, K. (eds) Kompendium Internistische Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-12175-7_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-12175-7_1

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-60830-1

  • Online ISBN: 978-3-662-12175-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation